Porto

• A Study to Investigate Efficacy, Pharmacokinetics, and Safety of Mirikizumab in Participants 2 Years to Less Than 18 Years of Age with Moder … Ended
  2022-502183-20-00 5 2024-02-26 Moderately to Severely Active Ulcerative Colitis
• Bioequivalence of Apixaban 5 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions. Ended
  2023-506844-18-00 2 2024-01-10 No medical condition.
• Comparative Bioavailability of Ruxolitinib 20 mg Film-Coated Tablets in Healthy Participants Under Fasting Conditions. Ended
  2023-508339-29-00 2 2023-12-26 No medical condition.
• Bioequivalence of Tofacitinib 10 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions. Ended
  2023-504516-15-00 2 2023-12-18 No medical condition.
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the … Ended
  2023-503614-80-00 5 2023-12-14 Pulmonary Arterial Hypertension
• Ph 3b, BIC/FTC/TAF to DTG/3TC FDC, 96 Week switch, efficacy, safety, and tolerability study in ART-experienced older adults living with HIV … Ended
  2022-503137-66-00 5 2023-11-29 Human immunodeficiency virus (HIV)
• Pharmacokinetics of Nicorandil 40 mg Extended-Release Capsules in Healthy Subjects Under Fasting and Fed Conditions. Ended
  2023-506085-31-00 3 2023-11-27 No medical condition.
• Exploratory Bioavailability of Two Formulations of Gliclazide MR Tablets 120 mg (I.R.I.S.) in Healthy Volunteers Under Fed and Fasting Condi … Ended
  2023-507802-15-00 3 2023-11-07 Type 2 diabetes mellitus
• A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE) Ended
  2022-502227-22-00 4 2023-10-25 Autoimmune disease
• A study to test whether spesolimab helps people with a skin disease called hidradenitis suppurativa Ended
  2022-501074-19-00 10 2023-10-13 Hidradenitis suppurativa
• A study to learn how well a higher amount of aflibercept given as an injection into the eye works and how safe it is in people with reduced … Ended
  2022-502174-16-00 5 2023-09-13 Macular edema secondary to retinal vein occlusion
• Comparative Bioavailability of Empagliflozin 25 mg Film-Coated Tablets: A Single-Dose, Open-Label, Randomized, Two-Sequence, Two-Treatment, … Ended
  2023-506416-41-00 2 2023-09-11 No medical condition
• Bioequivalence of Ulipristal 30 mg Tablets in Healthy Subjects Under Fasting Conditions Ended
  2023-504258-36-00 2 2023-09-01 No medical condition
• Comparative Bioavailability of Midazolam 7.5 mg/1.5 mL Oromucosal Solution (Buccolam®) Versus 10 mg/2 mL Solution for Injection (Hypnovel®) … Ended
  2023-504903-10-00 2 2023-08-16 No medical condition.
• A study to evaluate Intravitreal JNJ-81201887(AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary … Ended
  2022-500746-16-00 4 2023-08-11 Geographic Atrophy
• Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE2) Ended
  2022-502000-73-00 5 2023-08-11 Focal Onset Seizures
• A Phase 1 Study to Investigate the Effect of Food on the Bioavailability of a Single Cytisinicline 3 mg Tablet and Evaluation of the Pharmac … Ended
  2023-504260-42-00 3 2023-08-08 No medical condition
• Initiation of angiotensin receptor-neprilysin inhibitor (ARNi) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with heart … Ended
  2022-502409-14-00 11 2023-08-04 Heart failure with reduced ejection fraction
• Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD (ACTIVATE study) Ended
  2022-501783-18-00 4 2023-07-21 Parkinson’s Disease
• Bioequivalence of Etonogestrel 68 mg Implant in Healthy Pre-Menopausal, Nonpregnant Female Subjects. Ended
  2023-504523-83-00 2 2023-06-29 No medical condition
• Bioequivalence of Etonogestrel 68 mg Implant in Healthy Pre-Menopausal, Nonpregnant Female Subjects. Ended
  2023-504527-40-00 2 2023-06-29 No medical condition
• Phase 2b Study to Assess Efficacy and Safety of Batoclimab in Adult Participants with Active CIDP. Ended
  2024-512646-42-00 4 2023-06-27 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• Bioequivalence of Eltrombopag 75 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions Ended
  2022-502701-15-00 2 2023-06-07 Thrombocytopenia
• Overactive Bladder Treatment with Xeomin and Vibe Delivery System (XAVIER) Ended
  2022-501759-95-00 4 2023-06-05 Overactive bladder (OAB)

Showing 457–480 of 548 trials